Jon Marc Wigginton Sells 5,000 Shares of MacroGenics Inc (MGNX) Stock

MacroGenics Inc (NASDAQ:MGNX) SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jon Marc Wigginton also recently made the following trade(s):

  • On Tuesday, November 21st, Jon Marc Wigginton sold 5,000 shares of MacroGenics stock. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00.
  • On Wednesday, October 25th, Jon Marc Wigginton sold 10,000 shares of MacroGenics stock. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00.

MacroGenics Inc (MGNX) opened at $19.19 on Friday. The firm has a market cap of $717.85, a PE ratio of -4.27 and a beta of 2.73. MacroGenics Inc has a 52-week low of $14.36 and a 52-week high of $22.31.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.19). The business had revenue of $1.70 million for the quarter, compared to analyst estimates of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The business’s revenue was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.97) earnings per share. research analysts forecast that MacroGenics Inc will post -0.7 EPS for the current fiscal year.

A number of research analysts have weighed in on MGNX shares. Cowen reaffirmed a “buy” rating on shares of MacroGenics in a report on Wednesday, October 25th. ValuEngine cut shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Citigroup boosted their target price on shares of MacroGenics from $18.00 to $22.00 and gave the stock a “neutral” rating in a research note on Friday, November 10th. Finally, BidaskClub raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. MacroGenics presently has a consensus rating of “Buy” and an average price target of $30.10.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cornerstone Capital Management Holdings LLC. boosted its position in MacroGenics by 43.9% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 33,438 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 10,200 shares during the last quarter. Tocqueville Asset Management L.P. boosted its holdings in MacroGenics by 33.3% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 100,000 shares of the biopharmaceutical company’s stock valued at $1,848,000 after purchasing an additional 25,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in MacroGenics by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,391,322 shares of the biopharmaceutical company’s stock valued at $24,362,000 after purchasing an additional 38,458 shares during the last quarter. Hood River Capital Management LLC boosted its holdings in MacroGenics by 2.2% in the 3rd quarter. Hood River Capital Management LLC now owns 588,799 shares of the biopharmaceutical company’s stock valued at $10,881,000 after purchasing an additional 12,606 shares during the last quarter. Finally, Pinnacle Associates Ltd. boosted its holdings in MacroGenics by 38.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 843,175 shares of the biopharmaceutical company’s stock valued at $15,582,000 after purchasing an additional 233,657 shares during the last quarter. Hedge funds and other institutional investors own 85.77% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Jon Marc Wigginton Sells 5,000 Shares of MacroGenics Inc (MGNX) Stock” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/20/jon-marc-wigginton-sells-5000-shares-of-macrogenics-inc-mgnx-stock.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply